Conmed

Conmed Equity Growth

The Year-over-Year Equity Growth of Conmed (CNMD) as of Nov 13, 2026 is 7.31 %. In the previous year, Year-over-Year Equity Growth was 15.40 % — a change of -52.50% (lower).

Equity Growth

7.31 %

YoY

-52.50%

Last updated:

Year-over-Year Equity Growth of Conmed is 2025 7.31 % . Year-over-Year Equity Growth of Conmed was 2024 15.40 % . It decreases by -52.50% lower compared to the previous year.

The Conmed Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2018
4.88 USD
Jan 1, 2019
7.28 USD
Jan 1, 2020
-0.20 USD
Jan 1, 2021
10.77 USD
Jan 1, 2022
-5.08 USD
Jan 1, 2023
11.89 USD
Jan 1, 2024
15.40 USD
Jan 1, 2025
7.31 USD
The Conmed Equity Growth history
YEAREquity GrowthYoY
7.31 %-52.50%
15.40 %+29.46%
11.89 %-334.20%
-5.08 %-147.14%
10.77 %-5,456.96%
-0.20 %-102.76%
7.28 %+49.01%
4.88 %-44.25%
8.76 %-1,239.65%
-0.77 %-218.36%
0.65 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Conmed Stock analysis

What does Conmed do? Conmed Corporation is a leading medical technology company that offers a wide range of surgical instruments and devices for the fields of gastroenterology, endoscopy, orthopedics, gynecology, and electro surgery. The company was founded in 1970 and is headquartered in Utica, New York. The history of Conmed Corp began with the founding of Consolidated Medical Equipment, Inc. (CME) in 1970. The company initially started its business with the distribution of surgical instruments and devices for medical applications and quickly expanded in this field. In the 1980s, the company went public. In the 1990s, the company changed its name to Conmed Corporation and expanded its activities into the field of electro surgery, which has since become a major growth driver for the company. Today, Conmed Corp operates multiple manufacturing facilities worldwide and has sales offices in over 50 countries. The company is divided into four main business segments: gastroenterology, endoscopy, orthopedics, and electro surgery. The gastroenterology segment includes products for the diagnosis and treatment of gastrointestinal disorders, such as endoscopes, biopsy instruments, dilation balloons, trocars, and shears. In the endoscopy segment, Conmed Corp offers products for the diagnosis and treatment of digestive tract disorders, including endoscopes, biopsy instruments, dilation balloons, trocars, and shears. The orthopedics segment includes a wide range of surgical instruments and devices for the treatment of musculoskeletal disorders, including implants, bandages, bone plates, intramedullary nails, and others. Finally, the electro surgery segment is the fastest-growing segment of Conmed Corp and includes a wide range of devices for precision surgery, including electrocautery, electro surgery, endoscopy, and laparoscopy devices. Conmed Corp aims to develop innovative medical technologies that meet the needs of patients and healthcare professionals. The company places great emphasis on producing high-quality products that are reliable and safe. Conmed Corp is a successful company that continues to evolve and expand its product range to meet the rapidly evolving needs of the medical community. Conmed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Conmed stock

Year-over-Year Equity Growth of Conmed is 7.31 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Conmed since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Conmed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Conmed

All Key Metrics — Conmed